低剂量CT筛查阴性后的肺癌发病与死亡风险
该前瞻性队列研究基于中国国家肺癌筛查计划2012—2019年省级数据,纳入269,173名40—74岁参与者,中位随访8.61年。与未筛查组相比,筛查阴性组的肺癌发病风险(HR 0.80)和全因死亡风险(HR 0.77)显著降低,但肺癌特异性死亡无显著差异(HR 0.88)。阴性组长期风险与低风险人群相当,支持风险分层随访而非统一年度复查。
要点
- LDCT筛查阴性者肺癌发病和全因死亡风险显著低于未筛查人群。
- 阴性组肺癌特异性死亡风险与未筛查组无显著差异。
- 阴性组长期风险与低风险人群相当,支持风险分层随访。
核心结论
- LDCT筛查阴性者长期肺癌发病、死亡及全因死亡风险与低风险人群相当,支持风险分层随访而非统一年度复查。
研究设计与样本
- 前瞻性队列研究,基于中国国家肺癌筛查计划2012—2019年省级数据,纳入269,173名40—74岁参与者,中位随访8.61年。
主要发现
- 随访期间共发生3,173例肺癌和2,083例肺癌死亡。
- 与未筛查组相比,阴性组肺癌发病风险HR 0.80(95%CI 0.65-0.97),全因死亡风险HR 0.77(95%CI 0.70-0.85)。
- 阴性组肺癌特异性死亡与未筛查组无显著差异,HR 0.88(95%CI 0.69-1.12)。
- 阴性组与低风险组肺癌发病(HR 0.84,95%CI 0.68-1.03)、肺癌死亡(HR 0.89,95%CI 0.69-1.15)及全因死亡(HR 0.91,95%CI 0.80-1.05)风险相当。
- 目前吸烟且筛查阴性者长期肺癌发病风险高于低风险组。
临床怎么用
- 对LDCT筛查阴性者可按风险分层制定随访间隔,而非统一年度复查。
- 目前吸烟的筛查阴性者仍需关注长期肺癌发病风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Chest . 2026 Jul 1:S0012-3692(26)00936-0. doi: 10.1016/j.chest.2026.05.049. Online ahead of print. ABSTRACT BACKGROUND: The clinical value of a negative low-dose CT (LDCT) screening result for long-term risk stratification remains unclear, leading to uncertainties in rescreening intervals. RESEARCH QUESTION: What are the long-term risks of lung cancer incidence and mortality among individuals with negative screening results? STUDY DESIGN AND METHODS: This prospective cohort study used data from provincial initiatives (2012-2019) within China's National Lung Cancer Screening Program. Participants 40 to 74 years of age were categorized as nonscreened, negative screening results, positive screening results, or low risk. Inverse probability weighting integrated with Cox proportional hazard models was used to estimate the hazard ratios (HRs) and 95% CIs for lung cancer incidence and mortality. RESULTS: During a median follow-up of 8.61 years, 3,173 incident lung cancers and 2,083 lung cancer deaths occurred among 269,173 participants. Compared with the nonscreened group, the group with negative screening results exhibited a significantly lower risk of lung cancer incidence (HR, 0.80; 95% CI, 0.65-0.97) and all-cause mortality (HR, 0.77; 95% CI, 0.70-0.85), whereas lung cancer-specific mortality did not differ significantly (HR, 0.88; 95% CI, 0.69-1.12). The reduced risk of lung cancer persisted throughout follow-up and was most pronounced during the first 3 years. Although the group with negative screening results exhibited lung cancer incidence (HR, 0.84; 95% CI, 0.68-1.03), lung cancer mortality (HR, 0.89; 95% CI, 0.69-1.15), and all-cause mortality (HR, 0.91; 95% CI, 0.80-1.05) comparable with those in the low-risk group, a slightly lower risk of lung cancer was observed in the group with negative screening results at the 9-year cumulative follow-up. In stratified analyses, individuals who were currently smoking with negative screening results showed a higher long-term risk of lung cancer incidence than those in the low-risk group. INTERPRETATION: Our results show that individuals with negative LDCT screening results generally had long-term risks of lung cancer incidence, mortality, and all-cause mortality comparable with those of the low-risk population, supporting risk-stratified follow-up, rather than uniform annual rescreening. PMID: 42385994 | DOI: 10.1016/j.chest.2026.05.049
引用
- PubMed 顶刊 · 肺结节与肺癌筛查:Lung Cancer Incidence and Mortality After Negative Low-Dose CT Imaging Screening Results
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。